A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

Starting soon · Phase 1

Conditions studied: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease

In brief

This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).

Key facts

Study ID

NCT07649265

Run by

Otsuka Pharmaceutical Development & Commercialization, Inc.

People needed

63

Starts

2026-09-15

Expected to finish

2028-11-20

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.